이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

3 단계 시험 시험 시험은 EOC, Ollopian Tube 또는 1 차 복막 암이있는 새로 진단 된 환자에서 표준 NACT 및 보조 화학 요법과 함께 조합하여 IMNN-001의 안전성 및 효능을 평가합니다. (OVATION-3)

2026년 11월 11일 업데이트: Imunon

EOC, Ollopian Tube 또는 1 차 복구암이있는 새로 진단 된 환자에서 표준 Neoadjuvant 및 Advuvant 화학 요법과 함께 조합 된 IP IMNN-001의 안전성 및 효능을 평가하는 무작위 3 상 시험.

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Eligible participants will be randomly assigned 1:1 to receive either chemotherapy plus IMNN-001 or chemotherapy alone, followed by standard of care maintenance therapy.

Randomization will stratify by confirmed biomarker tumor homologous recombination deficiency status and stage of cancer.

On both arms, the chemotherapy regimen will consist of paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1 of each cycle. This will be repeated every 3 weeks for a total of 6 cycles, 3 in the neoadjuvant period and 3 in the adjuvant period following interval debulking surgery (IDS). On the experimental arm, IMNN-001 at a dose of 100 mg/m2 will be administered IP on Days 8 and 15 of the first chemotherapy cycle and then on Days 1, 8, and 15 of all subsequent 5 chemotherapy cycles for a total of 17 treatments in the neoadjuvant and adjuvant settings. When given on the same day as chemotherapy, IMNN-001 should be given at least 30 minutes after completion of carboplatin infusion. IDS will take place after 3 cycles of neoadjuvant chemotherapy (NACT) + IMNN-001 for 8 doses. Additional cycles of NACT are allowed at the discretion of the investigator but with discussion with the medical monitor.

An independent Data Monitoring Committee (iDMC) will monitor participants' safety and study conduct throughout the course of the trial.

연구 유형

중재적

등록 (추정된)

500

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Douglas Faller, M.D.
  • 전화번호: +1 609 896 9100
  • 이메일: dfaller@imunon.com

연구 연락처 백업

연구 장소

    • Florida
    • Louisiana
      • New Orleans, Louisiana, 미국, 70112
        • 모병
        • Louisiana State University HSC - NO Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Amelia Jernigan, M.D.
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • 모병
        • Karmanos Cancer Institute
        • 연락하다:
        • 수석 연구원:
          • Robert Morris, M.D.
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55455
        • 모병
        • Masonic Cancer Center, University of Minnesota
        • 연락하다:
        • 수석 연구원:
          • Melissa Geller, M.D.
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Washington University School of Medicine in St. Louis
        • 수석 연구원:
          • Andrea Hagemann, MD
        • 연락하다:
    • New York
      • Rochester, New York, 미국, 14642
        • 모병
        • University of Rochester Medical Center
        • 연락하다:
          • Mckenzie McLoughlin
        • 수석 연구원:
          • Richard Moore, M.D.
    • Oregon
      • Portland, Oregon, 미국, 97213
        • 모병
        • Providence Cancer Institute
        • 연락하다:
        • 수석 연구원:
          • Christopher Darus, MD
    • South Dakota
      • Sioux Falls, South Dakota, 미국, 57104
    • Tennessee
    • Washington
      • Spokane, Washington, 미국, 99204
        • 모병
        • Providence Sacred Heart Medical Center & Children's Hospital
        • 수석 연구원:
          • Melanie Bergman, MD
        • 연락하다:
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • 모병
        • Froedtert and The Medical College of Wisconsin
        • 수석 연구원:
          • William Bradley, MD
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  1. Participants must be female, ≥18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent.

  2. Participants with a histologically confirmed diagnosis of high-grade non-mucinous epithelial ovarian (serous, endometrioid, carcinosarcoma, mixed epithelial pathologies), fallopian tube or peritoneal cancer that is Stage IIIB/C or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria.

  3. Participants eligible to receive neoadjuvant chemotherapy.

  4. Participants will provide a tumor tissue sample at pre-screening or screening, via laparoscopy or image guided core biopsy for determination of confirmed biomarker tumor status (HRD vs. HRP). See biomarker status definitions in the section below.

  5. Participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin) within 14 days prior to initiation of protocol therapy and be practicing an effective form of contraception. If applicable, participants must discontinue breastfeeding prior to study entry.

  6. Participants must have adequate:

    1. Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/µl. Exceptions may be made in patients with benign ethnic neutropenia >800/ul with approval of a medical monitor. This ANC cannot have been induced or supported by granulocyte colony stimulating factors. Platelets greater than or equal to 100,000/µl.
    2. Renal function: eGFR > 60 ml/min/1.73m2
    3. Hepatic function: Bilirubin ≤ 1.5 x ULN. SGOT (AST) and SGPT (ALT) ≤ 3.0 x ULN and alkaline phosphatase ≤ 2.5 x ULN. Exceptions due to hepatic metastases can be considered in consultation with medical monitor.
    4. Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1 as defined by CTCAE version 5.0.
  7. Participants must have an ECOG score of 0, 1 or 2.

  8. Participants should be free of active infection requiring parenteral antibiotics or a serious uncontrolled medical illness or disorder within 4 weeks of study entry.

  9. Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to the first treatment. Continuation of hormone replacement therapy is permitted.

Exclusion Criteria:

  1. Participant who has received prior treatment with IMNN-001.
  2. Participant who has received oral or parenteral corticosteroids (>10 mg prednisone) within 2 weeks of first dose of IMNN-001 (if applicable) or who have a clinical requirement for ongoing systemic immunosuppressive therapy such as chronic steroid use not related to chemotherapy administration.
  3. Participant has mucinous, germ cell, transitional cell, clear cell, undifferentiated, or non-epithelial ovarian cancer.
  4. Participant has low-grade or Grade 1 epithelial ovarian cancer.
  5. Participant of childbearing potential, not practicing adequate contraception, participant who is pregnant, or participant who is breastfeeding are not eligible for this trial.
  6. Participant has a bowel obstruction by clinical symptoms or computed tomography (CT) scan, sub-occlusive mesenteric disease, abdominal or gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess.
  7. Participant has been diagnosed and/or treated with any therapy for invasive cancer <3 years from study enrollment, completed adjuvant chemotherapy and/or targeted therapy at least 3 years from enrollment, or completed adjuvant hormonal therapy less than 4 weeks from enrollment.
  8. Participant with definitively treated non-invasive malignancies such as cervical carcinoma in situ, ductal carcinoma in situ, grade 1 or 2 Stage IA endometrioid endometrial cancer, or non-melanomatous skin cancer are allowed.
  9. Participant with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the participant to extreme risk or decreased life expectancy.
  10. Participant has known active hepatitis or HIV with detectable viral load.
  11. Participant has a known contraindication or uncontrolled hypersensitivity to the components of paclitaxel, carboplatin, IMNN-001, or their excipients.
  12. Prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., immunotherapy, anticancer therapy, surgery, radiation therapy).
  13. Participant is receiving treatment for active autoimmune disease. "Active" refers to any condition currently requiring therapy. Examples of autoimmune disease include systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.
  14. Participant who has received prior radiotherapy to any portion of the abdominal cavity or pelvis is excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, if it was completed at least 3 years prior to registration, and the participant remains free of recurrent or metastatic disease.
  15. Participant who has received prior chemotherapy for any abdominal or pelvic tumor is excluded. Participant may have received prior adjuvant chemotherapy for localized breast cancer, if it was completed at least three years prior to registration, and that the participant remains free of recurrent or metastatic disease.
  16. Participant with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.
  17. Participant who will receive bevacizumab with the neoadjuvant or adjuvant treatment, or as maintenance will be excluded.
  18. Participant with any condition/anomaly that would interfere with the appropriate placement of the IP catheter for study drug administration including abdominal surgery within 4 weeks of study entry (for reason other than IP port placement or laparoscopic diagnosis of epithelial ovarian cancer), intestinal dysfunction as defined in #6 above.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Experimental Arm: IMNN-001 + SOC Chemotherapy + SOC Maintenance Therapy

IMNN-001 in combination with standard neoadjuvant and adjuvant chemotherapy followed by standard of care maintenance therapy

100 mg/m2 IP given weekly during frontline treatment

다른 이름들:
  • 1세대

175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment

AUC 6 IV given every 21 days for 6 cycles during frontline treatment

Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.

다른 이름들:
  • 린파자

Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut & HRD/BRCAwt.

다른 이름들:
  • 제줄라
활성 비교기: Control Arm: SOC Chemotherapy + SOC Maintenance Therapy

Standard neoadjuvant and adjuvant chemotherapy followed by standard of care maintenance therapy.

175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment

AUC 6 IV given every 21 days for 6 cycles during frontline treatment

Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.

다른 이름들:
  • 린파자

Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut & HRD/BRCAwt.

다른 이름들:
  • 제줄라

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall Survival
기간: 48 months

Overall Survival is defined as the time (in months) from the date of randomization to the date of death by any cause.

48 months

2차 결과 측정

결과 측정
측정값 설명
기간
Chemotherapy Response Score
기간: 12 weeks

After the interval debulking surgery takes place, participants will be assessed for a chemotherapy response score by the pathologist and scored based on CRS3, CRS2, or CRS1.

12 weeks
Surgical Response
기간: 12 weeks

After the interval debulking surgery takes place, participants are scored in terms of their interval debulking status with a score of R0, R1, or R2.

12 weeks
Time to Second Line Treatment
기간: 13 months

Time to second line treatment is defined as the time (in months) from the date of randomization to the date of second line chemotherapy treatment or death, whichever occurs first.

13 months
Objective Response Rate
기간: 12 weeks

Objective Response Rate is defined as the proportion of participants with objective evidence of CR or PR prior to IDS. The evaluation of objective response rate will be based on investigator (site) assessment of the images following RECIST v1.1 criteria.

12 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 의자: Premal H Thaker, M.D., Washington University School of Medicine

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 7월 9일

기본 완료 (추정된)

2032년 10월 31일

연구 완료 (추정된)

2032년 10월 31일

연구 등록 날짜

최초 제출

2025년 4월 1일

QC 기준을 충족하는 최초 제출

2025년 4월 1일

처음 게시됨 (실제)

2025년 4월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .